{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-015708","form_type":"8-K","ticker":"PETV","cik":"0001512922","company_name":"PetVivo Holdings, Inc.","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.553243+00:00","generated_at":"2026-05-19T01:16:09.732371+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PetVivo receives $3M from partial exercise of Series B convertible preferred stock purchase option","bullets":["Received $3,000,000 from partial exercise of Purchase Option; total proceeds to date $4,000,000 out of $5,000,000 offering.","Remaining $1,000,000 expected by June 26, 2025; shares priced at $1.00 each, convertible 1:1 to common stock.","Proceeds to fund commercialization of Spryng™ and PrecisePRP, clinical trials, and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-015708","json":"https://secwatch.observer/filing/0001641172-25-015708.json","markdown":"https://secwatch.observer/filing/0001641172-25-015708.md","text":"https://secwatch.observer/filing/0001641172-25-015708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512922/000164117225015708/0001641172-25-015708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512922/000164117225015708/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T01:16:09.732371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}